ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

15 Health Benefits of Chia Seeds, According to Science

Tangerine Oil: A Citrusy Essential Oil With Well-Rounded Uses

Natural Remedies for the Prevention of Dry Eyes

Magnesium Deficiency Raises Your Risk of Many Chronic Ailments

Resveratrol supplementation improves arterial stiffness in type 2 diabetics

CoQ10's Potential Capabilities for Your Health

How Can Melatonin Benefit You?

Cloves: Boost Your Immune System the Sweet and Spicy Way

8 Chia Seed Recipes

Cinnamon Health Benefits Proven

 
Print Page
Email Article

Randomized, Placebo-controlled, Double-blind Trial of Valomaciclovir (VALM) for Infectious Mononucleosis (IM) – Source: Interscience Conference on Antimicrobial Agents & Chemotherapy, Sep 14, 2009

  [ 15 votes ]   [ Discuss This Article ]
By Henry H Balfour Jr., et al. • www.ProHealth.com • September 16, 2009


[Note: As described in a Los Angeles Times article, “Antiviral drug found to reduce severity of mono,” viral load was reduced in treated youngsters, who averaged a 50% symptom improvement in 7.6 days vs. 11.1 days for placebo. The next challenge: identify factors that may justify treatment – e.g., characteristics that appear linked to more severe illness, or to later development of illnesses such as ME/CFS.]

Background: Infectious mononucleosis (IM) causes substantial loss of productivity in teenagers and young adults. We conducted an investigator-initiated clinical trial of the guanosine nucleoside prodrug Valomaciclovir (VALM) for infectious mononucleosis under an investigator IND.

Methods: Subjects over the age of 15 with acute infectious mononucleosis were randomized to 21 days of VALM 4 g/day or placebo (PBO) and followed for 6 mo. Clinical, virologic, immunologic and pharmacologic observations were made during 10 visits.

Results:
21 subjects ages 16 to 24 yr (median age, 19.6 yr) enrolled a median of 6 days after onset of infectious mononucleosis confirmed due to primary Epstein-Barr virus (EBV) infection. 11 were assigned to VALM and 10 to PBO.

• VALM subjects had significantly faster clinical improvement than PBO recipients as documented by comparing the slopes of the plots of their physical exam/symptom scores from each visit during the treatment period (95% confidence intervals did not overlap; P<0.05).

• Severity of illness and SF12 scores improved faster in VALM subjects but rates were not statistically significant.

• VALM produced a significant decrease in median EBV load in the oral compartment vs PBO (oral cell pellet, P=0.03; oral supernatant, P=0.001, unpaired t test, 2-sided).

• The proportion of subjects who had at least a 2 log10 decrease in EBV load in the oral compartment was also significantly different (VALM 8/11; PBO 2/10; P=0.03, Fisher exact test, 2-sided).

• No differences were found in clearance of EBV DNAemia, CD8:CD4 ratios, CD8 lymphocytosis, or CD8 responses to lytic and latent EBV tetramers in the VALM vs PBO subjects.

• 9 of 11 VALM subjects had at least 1 plasma concentration of H2G, the parent compound of VALM, above the in vitro IC50 for EBV in subject-derived lymphoblastoid cells, which is 2.1 micromolar.

Conclusions:
This is the first demonstration of a clinical benefit and an in vivo antiviral effect of VALM in acute infectious mononucleosis due to primary EBV infection.

This study encourages additional investigation of the role of VALM in the management of diseases associated with EBV.

[ClinicalTrials.gov Trial: NCT00575185]

Source: Interscience Conference on Antimicrobial Agents & Chemotherapy, Sep 14, 2009, San Francisco. Presentation Number V-1256a; Session 146 – Herpes Viruses and Other Viral Infections in Immunocompromised Hosts. By Balfour HH, Vezina HE, Hogquist KA, Brundage RC, Anderson BJ, Odumade OA. University of Minnesota, Minneapolis, USA.





Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Mitochondria Ignite™ with NT Factor® Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Aching Muscles? Top 10 Nutrients to Take Back Your Life Aching Muscles? Top 10 Nutrients to Take Back Your Life
Vitamin K-2 – A Key Player in Cardiovascular and Bone Health Vitamin K-2 – A Key Player in Cardiovascular and Bone Health
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
How I Found My Long-Lost Energy How I Found My Long-Lost Energy

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map